bluuebunny/crossref_metadata_2025_split huggingface dataset:
European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria
Authors: Lepape Alain , Jean Astrid , De Waele Jan , Friggeri Arnaud , Savey Anne , Vanhems Philippe , Gustin Marie Paule , Monnet Dominique L. , Garnacho-Montero José , Kohlenberg Anke 
Published: January 2020

Abstract
Background
Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate therapeutic options. A survey was conducted to assess the intensive care physicians’ perception of the AMR situation in the European Union/European Economic Area (EU/EEA).

Methods
Between May and July 2017, physicians working in European ICUs were invited to complete an online questionnaire hosted by the European Society of Intensive Care Medicine. The survey included 20 questions on hospital and ICU characteristics, frequency of infections with multidrug-resistant (MDR) bacteria and relevance of AMR in the respondent’s ICU, management of antimicrobial treatment as well as the use of last-line antibiotics in the six months preceding the survey. For the analysis of regional differences, EU/EEA countries were grouped into the four sub-regions of Eastern, Northern, Southern and Western Europe.

Results
Overall, 1062 responses from four European sub-regions were analysed. Infections with MDR bacteria in their ICU were rated as a major problem by 257 (24.2%), moderate problem by 360 (33.9%) and minor problem by 391 (36.8%) respondents. Third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently encountered MDR bacteria followed by, in order of decreasing frequency, meticillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and vancomycin-resistant enterococci. Perception of the relevance of the AMR problem and the frequency of specific MDR bacteria varied by European sub-region. Bacteria resistant to all or almost all available antibiotics were encountered by 132 (12.4%) respondents. Many physicians reported not having access to specific last-line antibiotics.

Conclusions
The percentage of European ICU physicians perceiving AMR as a substantial problem in their ICU is high with variation by sub-region in line with epidemiological studies. The reports of bacteria resistant to almost all available antibiotics and the limited availability of last-line antibiotics in ICUs in the EU/EEA are of concern.
Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy
Authors: Nelson Barbara S. , Lin Lin , Kremer Daniel M. , Sousa Cristovão M. , Cotta-Ramusino Cecilia , Myers Amy , Ramos Johanna , Gao Tina , Kovalenko Ilya , Wilder-Romans Kari , Dresser Joseph , Davis Mary , Lee Ho-Joon , Nwosu Zeribe C. , Campit Scott , Mashadova Oksana , Nicolay Brandon N. , Tolstyka Zachary P. , Halbrook Christopher J. , Chandrasekaran Sriram , Asara John M. , Crawford Howard C. , Cantley Lewis C. , Kimmelman Alec C. , Wahl Daniel R. , Lyssiotis Costas A. 
Published: January 2020

Abstract
Background
Metabolic programs in cancer cells are influenced by genotype and the tissue of origin. We have previously shown that central carbon metabolism is rewired in pancreatic ductal adenocarcinoma (PDA) to support proliferation through a glutamate oxaloacetate transaminase 1 (GOT1)-dependent pathway.

Methods
We utilized a doxycycline-inducible shRNA-mediated strategy to knockdown GOT1 in PDA and colorectal cancer (CRC) cell lines and tumor models of similar genotype. These cells were analyzed for the ability to form colonies and tumors to test if tissue type impacted GOT1 dependence. Additionally, the ability of GOT1 to impact the response to chemo- and radiotherapy was assessed. Mechanistically, the associated specimens were examined using a combination of steady-state and stable isotope tracing metabolomics strategies and computational modeling. Statistics were calculated using GraphPad Prism 7. One-way ANOVA was performed for experiments comparing multiple groups with one changing variable. Student’s t test (unpaired, two-tailed) was performed when comparing two groups to each other. Metabolomics data comparing three PDA and three CRC cell lines were analyzed by performing Student’s t test (unpaired, two-tailed) between all PDA metabolites and CRC metabolites.

Results
While PDA exhibits profound growth inhibition upon GOT1 knockdown, we found CRC to be insensitive. In PDA, but not CRC, GOT1 inhibition disrupted glycolysis, nucleotide metabolism, and redox homeostasis. These insights were leveraged in PDA, where we demonstrate that radiotherapy potently enhanced the effect of GOT1 inhibition on tumor growth.

Conclusions
Taken together, these results illustrate the role of tissue type in dictating metabolic dependencies and provide new insights for targeting metabolism to treat PDA.
Shades of blue: non-invasive spectroscopic investigations of Maya blue pigments. From laboratory mock-ups to Mesoamerican codices
Authors: Grazia Chiara , Buti David , Amat Anna , Rosi Francesca , Romani Aldo , Domenici Davide , Sgamellotti Antonio , Miliani Costanza 
Published: January 2020

Abstract
Maya blue is a hybrid pigment where an organic component, indigo, is incorporated in a porous clay. Despite its widespread use in the Mesoamerican artistic production and numerous studies devoted to understand the type of interactions between indigo and the host framework, its technology has not been completely unravelled yet. In this study portable non-invasive UV–vis reflection spectroscopy is proposed as a robust method for in situ investigation of Maya blue pigments. Laboratory mock-ups of powder Maya blue have been prepared employing different synthesis procedures (varying the nature of: clays, indigo–clay ratios, heating temperatures and time). The goodness of the prepared Maya blue samples—namely the occurrence of indigo–clay interactions—have been probed by micro-Raman spectroscopy and related UV–vis spectral markers have been identified. DFT calculations as well have been performed to deeply explain UV–vis profiles. The set of spectral markers have been finally exploited to interpret spectra recorded on Mesoamerican pictorial codices, through a multi-technique approach based on exploring the UV–Vis properties of the blue paint supported by the FT-IR vibrational study of the inorganic clays. The characterization of blue colours on pre-Hispanic and colonial Mesoamerican codices contribute to a better understanding of the compositional variability of these painting materials and to point out the existence of different technological traditions of colour preparation in ancient Mesoamerica.
Dexmedetomidine improved renal function in patients with severe sepsis: an exploratory analysis of a randomized controlled trial
Authors:   DESIRE Trial Investigators, Nakashima Tsuyoshi , Miyamoto Kyohei , Shima Nozomu , Kato Seiya , Kawazoe Yu , Ohta Yoshinori , Morimoto Takeshi , Yamamura Hitoshi 
Published: January 2020

Abstract
Background
Dexmedetomidine has been reported to improve organ dysfunction in critically ill patients. In a recent randomized controlled trial (Dexmedetomidine for Sepsis in Intensive Care Unit (ICU) Randomized Evolution [DESIRE]), we demonstrated that dexmedetomidine was associated with reduced mortality risk among patients with severe sepsis. We performed this exploratory sub-analysis to examine the mechanism underlying improved survival in patients sedated with dexmedetomidine.

Methods
The DESIRE trial compared a sedation strategy with and without dexmedetomidine among 201 mechanically ventilated adult patients with sepsis across eight ICUs in Japan. In the present study, we included 104 patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of ≥ 23 (54 in the dexmedetomidine [DEX] group and 50 in the non-dexmedetomidine [non-DEX] group). Initially, we compared the changes in the sequential organ failure assessment (SOFA) scores from the baseline within 6 days after randomization between groups. Subsequently, we evaluated the variables comprising the organ component of the SOFA score that showed relevant improvement in the initial comparison.

Results
The mean patient age was 71.0 ± 14.1 years. There was no difference in the median APACHE II score between the two groups (29 [interquartile range (IQR), 25–31] vs. 30 [IQR, 25–33]; p = 0.35). The median SOFA score at the baseline was lower in the DEX group (9 [IQR, 7–11] vs. 11 [IQR, 9–13]; p = 0.01). While the renal SOFA subscore at the baseline was similar for both groups, it significantly decreased in the DEX group on day 4 (p = 0.02). During the first 6 days, the urinary output was not significantly different (p = 0.09), but serum creatinine levels were significantly lower (p = 0.04) in the DEX group. The 28-day and in-hospital mortality rates were significantly lower in the DEX group (22% vs. 42%; p = 0.03, 28% vs. 52%; p = 0.01, respectively).

Conclusion
A sedation strategy with dexmedetomidine is associated with improved renal function and decrease mortality rates among patients with severe sepsis.

Trial registration
This trial was registered on ClinicalTrials.gov (NCT01760967) on January 1, 2013.
Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin
Authors: Li Jieli , Chang Hui-Ming , Banchs Jose , Araujo Dejka M. , Hassan Saamir A. , Wagar Elizabeth A. , Yeh Edward T. H. , Meng Qing H. 
Published: January 2020

Abstract
Background
Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity. Recently, global longitudinal peak systolic strain (GLS) measured with speckle tracking echocardiography (STE) and high-sensitivity troponin T (hs-TnT) have been validated as sensitive indicators of doxorubicin-induced cardiotoxicity. Here, we asked whether changes in hs-TnT and/or GLS can be detected in patients who were treated with continuous infusion of doxorubicin or pre-treated with dexrazoxane followed by bolus doxorubicin.

Methods
Twenty-nine patients with newly diagnosed sarcoma were assigned to receive either 72-h doxorubicin infusion or dexrazoxane pre-treatment before bolus doxorubicin. Eight patients received dexrazoxane pre-treatment; eleven patients received continuous doxorubicin infusion; ten patients crossed over from continuous infusion to dexrazoxane. Bloods were collected for hs-TnT at baseline, 24 h or 72 h after initiation of doxorubicin treatment in each chemotherapy cycle. All blood samples were assayed in batch using hs-TnT kit from Roche diagnostics. 2D Echo and STE were performed before doxorubicin, after cycle 3, and at the end of chemotherapy.

Results
Seven patients in the cross-over group have at least one hs-TnT measurement between 5 ng/L to 10 ng/L during and after chemotherapy. Ten patients have at least one hs-TnT measurement above 10 ng/ml during and after chemotherapy (six in dexrazoxane group, three in continuous infusion group, one in cross-over group). The average hs-TnT level increases with each additional cycle of doxorubicin treatment. Eight patients had a more than 5% reduction in LVEF at the end of chemotherapy (four in dexrazoxane group, three in continuous infusion group, and one in cross-over group). Four out of these eight patients had a change of GLS by more than 15% (three in the dexrazoxane group).

Conclusion
Elevation in hs-TnT levels were observed in more than 59% of patients who had received either continuous doxorubicin infusion or dexrazoxane pre-treatment before bolus doxorubicin. However, changes in LVEF and GLS were less frequently observed. Thus, continuous doxorubicin infusion or dexrazoxane pre-treatment do not completely ameliorate subclinical doxorubicin-induced cardiotoxicity as detected by more sensitive techniques.
Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record
Authors: Maraganore Demetrius M. , Freedom Thomas , Simon Kelly Claire , Lovitz Lori E. , Musleh Camelia , Munson Richard , Nasir Nabeela , Patel Smita , Paul Joya , Viola-Saltzman Mari , Meyers Steven , Chesis Richard , Hillman Laura , Tideman Samuel , Pham Anna , Vazquez Rosa Maria , Frigerio Roberta 
Published: January 2020

Abstract
Background
We developed and implemented a structured clinical documentation support (SCDS) toolkit within the electronic medical record, to optimize patient care, facilitate documentation, and capture data at office visits in a sleep medicine/neurology clinic for patient care and research collaboration internally and with other centers.

Methods
To build our SCDS toolkit, physicians met frequently to develop content, define the cohort, select outcome measures, and delineate factors known to modify disease progression. We assigned tasks to the care team and mapped data elements to the progress note. Programmer analysts built and tested the SCDS toolkit, which included several score tests. Auto scored and interpreted tests included the Generalized Anxiety Disorder 7-item, Center for Epidemiological Studies Depression Scale, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Insomnia Severity Index, and the International Restless Legs Syndrome Study Group Rating Scale. The SCDS toolkits also provided clinical decision support (untreated anxiety or depression) and prompted enrollment of patients in a DNA biobank.

Results
The structured clinical documentation toolkit captures hundreds of fields of discrete data at each office visit. This data can be displayed in tables or graphical form. Best practice advisories within the toolkit alert physicians when a quality improvement opportunity exists. As of May 1, 2019, we have used the toolkit to evaluate 18,105 sleep patients at initial visit. We are also collecting longitudinal data on patients who return for annual visits using the standardized toolkits. We provide a description of our development process and screenshots of our toolkits.

Conclusions
The electronic medical record can be structured to standardize Sleep Medicine office visits, capture data, and support multicenter quality improvement and practice-based research initiatives for sleep patients at the point of care.
Trophic position and diet shift based on the body size of Coreoperca kawamebari (Temminck & Schlegel, 1843)
Authors: Choi Jong-Yun , Kim Seong-Ki , Kim Jeong-Cheol , Yoon Jung-Do 
Published: January 2020

Abstract
Background
Fish body size is a major determinant of freshwater trophic interactions, yet only a few studies have explored the relationship between the fish body size and trophic interactions in river upstream. In this study, we investigated the relationship between the body size and trophic position (TP) of Coreoperca kawamebari (Temminck & Schlegel, 1843) in an upstream of the Geum River.

Results
A stable isotope analysis (based on δ15N) was used to determine the TP based on the body size of C. kawamebari. The regression analysis (n = 33, f = 63.840, r2 = 0.68) clearly showed the relationship between the body length and TP of C. kawamebari. The TP of C. kawamebari was clearly divided by body size into the following classes: individuals of size < 10 cm that feed on insects and individuals of size > 10 cm feed on juvenile fish. This selective feeding is an evolutionarily selective tendency to maximize energy intake per unit time. Furthermore, the diet shift of C. kawamebari was led by different spatial distributions. The littoral zone was occupied by individuals of size < 10 cm, and those of size > 10 cm were mainly in the central zone. The littoral zone can be assumed to be enriched with food items such as ephemeropterans and dipterans.

Conclusion
The TP of C. kawamebari, as a carnivorous predator, will have a strong influence on biotic interactions in the upstream area of the Geum River, which can lead to food web implication.
The therapeutic role of Cannabidiol in mental health: a systematic review
Authors: Khan Rabia , Naveed Sadiq , Mian Nadeem , Fida Ania , Raafey Muhammad Abdur , Aedma Kapil Kiran 
Published: January 2020

AbstractBackgroundThe therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use.ObjectiveTo summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract fromCannabis sativaL. that has been purified into 1:1 ratio of CBD and delta-9-tetrahydrocannabinol) in the treatment of psychiatric disorders.Materials and methodA systematic review was conducted including case reports, case series, open-label trials, non-randomized and randomized controlled trials (RCTs). The search resulted in 23 relevant studies on CBD and nabiximols in the treatment of a wide range of psychiatric disorders. The quality of evidence was judged by using the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence that ranges from Level 1 to Level 5 based on the quality and study design. These levels of evidence help in grading the recommendations, including Grade A (strong), Grade B (moderate), Grade C (weak), and Grade D (weakest).ResultsCBD and CBD-containing compounds such as nabiximols were helpful in alleviating psychotic symptoms and cognitive impairment in patients with a variety of conditions, and several studies provided evidence of effectiveness in the treatment of cannabis withdrawal and moderate to severe cannabis use disorder with Grade B recommendation. There is Grade B recommendation supporting the use of CBD for the treatment of schizophrenia, social anxiety disorder and autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD). Grade C recommendation exists for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder, and Tourette syndrome. These recommendations should be considered in the context of limited number of available studies.ConclusionCBD and CBD-containing compounds such as nabiximols were helpful in alleviating symptoms of cannabis-related disorders, schizophrenia, social anxiety disorder, and comorbidities of ASD, and ADHD with moderate recommendation. However, there is weaker evidence for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder, and Tourette syndrome. The evidence for the use of CBD and CBD-containing compounds for psychiatric disorders needs to be explored in future studies, especially large-scale and well-designed RCTs.
Nonlinear L1 adaptive control of stagnation pressure in a cryogenic wind tunnel
Authors: Zhu Rusong , Xie Mingwei , Liao Daxiong , Tang Gengsheng , Gai Wen 
Published: January 2020

AbstractCryogenic wind tunnel is a sophisticated aerodynamics ground test facility, which operates in cryogenic temperature with injection of liquid nitrogen. The multi-variable, nonlinear and coupled dynamics existing between the temperature, pressure and Mach number in the tunnel, poses great challenges for the effective control of the tunnel. L1 adaptive control is a new control methodology developed in recent years with good robustness properties, which has good potentials to address these challenges. But this control method does not provide full adaptive feedforward control in its generic structure. In the paper, adaptive feedforward control action is introduced into the standard L1 adaptive control architecture for nonlinear systems in the presence of matched un-modeled dynamics. This new control structure is applied to the stagnation pressure control in a cryogenic wind tunnel, which could also be used for the control of temperature and Mach number in the tunnel. This new method could effectively compensate known disturbances with linear gain uncertainty, which occur in the nonlinear systems, while retaining the closed-loop control performance of L1 adaptive control. After the proof and discussions on the stability of this method, simulations of the stagnation pressure control in the wind tunnel are presented. The results and analysis demonstrate the effectiveness of the proposed control architecture.
Association of sleep duration and insomnia with menstrual symptoms among young women in Upper Egypt
Authors: Arafa Ahmed , Mahmoud Omaima , Abu Salem Entisar , Mohamed Abeer 
Published: January 2020

Abstract
Background
Disturbed sleep and menstrual symptoms are prevalent health conditions with limited successful treatments. This study aimed to detect the association between sleep problems and menstrual symptoms among young women in Upper Egypt. In this cross-sectional study, 4122 young women aged 12 to 25 years and residing in Beni-Suef City were recruited using a multi-stage random method. The participants were interviewed for their premenstrual disorders, dysmenorrhea, average daily hours of sleep, and insomnia during the previous 6 months.

Results
Young women who reported sleep < 8 and < 7 h/day had more premenstrual spasm than those who slept ≥ 8 h/day: OR 1.3, 95% CI 1.1–1.5 and OR 1.3, 95% CI 1.1–1.6, respectively. Hours of sleep were not associated with other menstrual symptoms. Compared with those without insomnia, young women with insomnia were more likely to report premenstrual spasm (OR 2.3, 95% CI 18–2.8), nervousness (OR 2.3, 95% CI 1.9–2.8), fatigue (OR 2.9, 95% CI 2.4–3.6), headache (OR 2.6, 95% CI 2.2–3.2), breast pain (OR 1.9, 95% CI 1.5–2.3), weight gain (OR 2.6, 95% CI 2.0–3.3), GIT disturbance (OR 2.8, 95% CI 2.2–3.6), and dysmenorrhea (OR 2.6, 95% CI 1.6–4.3).

Conclusion
Insomnia has been shown to be significantly associated with premenstrual symptoms and dysmenorrhea, but no substantial relationship has been indicated between hours of sleep and most menstrual symptoms.
Review on Tablet in Tablet techniques
Authors: Gaikwad Sachin S. , Kshirsagar Sanjay J. 
Published: January 2020

Abstract
Background
Among all available dosage form, tablet is most widely used because of its stability and patient acceptability. The better aesthetic quality like color, texture, mouth feel, and taste masking depended on film and sugar coatings, so the coating is an important part in the formulation of the tablet. The present work aims to comprehensively review the formulation, characterization, and challenges in the development of Tablet in Tablet dosage form.

Main text
Film and sugar coatings have the number of disadvantages; most important one is the utilization of aqueous or organic solvent that leads to toxicity. To overcome this problem in the year 1896, Noyes firstly introduced the compression coating or Tablet in Tablet technique. In the development of Tablet in Tablet dosage form, substantial attention among researchers and various research reports and patents inputs can be found in the literature. Also, we focused on the recent advancements in techniques like one-step dry-coating (OSDrC®) for manufacturing Tablet in Tablet dosage form.

Conclusion
The current review gathered information on the latest patent, formulation, advantages, and disadvantages of Tablet in Tablet or compression coating. The review also elaborates on the importance of Tablet in Tablet techniques in the development of a modified release system.

Graphical abstract
Parallels between wound healing, epimorphic regeneration and solid tumors
Authors: Wong Alan Y. , Whited Jessica L. 
Published: January 2020

ABSTRACT
Striking similarities between wound healing, epimorphic regeneration and the progression of solid tumors have been uncovered by recent studies. In this Review, we discuss systemic effects of tumorigenesis that are now being appreciated in epimorphic regeneration, including genetic, cellular and metabolic heterogeneity, changes in circulating factors, and the complex roles of immune cells and immune modulation at systemic and local levels. We suggest that certain mechanisms enabling regeneration may be co-opted by cancer to promote growth at primary and metastatic sites. Finally, we advocate that working with a unified approach could complement research in both fields.